Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 15/20 | 0.69 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.53 |
| ▸ | PDE5A | O76074 | 4/20 | 0.53 |
| ▸ | ACP1 | P24666 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14727822 | 0.89 | GBA1 (0.64) | GBA1PDE5AACP1 | |
| SCHEMBL14727827 | 0.87 | GBA1 (0.65) | GBA1PDE5AACP1 | |
| SCHEMBL14475595 | 0.84 | GBA1 (0.64) | GBA1ABCG2 | |
| SCHEMBL16184509 | 0.82 | GBA1 (0.53) | GBA1ABCG2 | |
| SCHEMBL14475591 | 0.82 | GBA1 (0.64) | GBA1ABCG2 | |
| SCHEMBL14475068 | 0.82 | CYP1A2 (0.64) | GBA1ABCG2PDE5A | |
| SCHEMBL15966672 | 0.82 | GBA1 (1.00) | GBA1PDE5AACP1 | |
| SCHEMBL18353968 | 0.82 | GBA1 (1.00) | GBA1PDE5AACP1 | |
| SCHEMBL18353876 | 0.82 | GBA1 (1.00) | GBA1PDE5AACP1 | |
| SCHEMBL14475181 | 0.81 | MEN1 (0.58) | GBA1ABCG2PDE5AACP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP2CA, PPP4C, PPP3CB | GBA1 1316/4885ABCG2 1597/4885PDE5A 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.